Hi everyone, Scotty here with ya! In this video, I give my view on recent market action, my short/mid/long term forecast moving forward, Biotech stock commentary, and a preview of 2 picks from stockmatusow.com for next week. Premium members get…
Tag: pharma
4 Biopharmas On Catalyst Watch List For Week 7/8/2013
Stockmatusow.com has compiled 4 biopharmas with significant near-term catalysts ahead that should drive their respective stock prices higher. We think each of these companies should also be looked at for speculation investments. Since the companies listed below are smaller caps,…
Wednesday’s Biotech Catalyst Trade Watch List
Today, I list four biotech companies with significant near-term catalysts ahead. Under normal market conditions, these stocks should see decent to very strong appreciation in the short-term. There are various ways to play these catalyst trades. Traders and investors can…
Trius and General Market Commentary 6/5/13
Trius and General Market Commentary 6/5/13.. Answering critics and explaining market cap to price. Business basics as well.
BioDelivery Sciences Primed To Grab Its Share Of The $1.5 Billion Opioid Market
These days, prescription drugs have become a source for legal and illegal abuse. This abuse can lead to a medical diagnosis called opioid dependence, which is when a patient that is addicted to opioids such as morphine, hydrocodone, oxycodone, or…
I bought BioDelivery Sciences (BDSI) on Bullish Chart: Solid Small Cap Spec Investment.
BioDelivery Sciences (BDSI) focuses on developing and commercializing products in the areas of pain management and oncology supportive care. The company uses its patented BioErodible MucoAdhesive (BEMA) and Bioral cochleate drug delivery technologies in the development of its products. …
Insmed Chart technicals with my opinion and explanation: YouTube Video
Insmed Chart technicals with my opinion and explanation: YouTube Video below, enjoy!
Significant Near-Term Top-Line Data Catalyst And Platform Technology Should Rally Insmed
The Orphan Drug Act was passed in January 1983 to encourage companies to develop drugs that treat rare medical conditions. Companies that receive Orphan Drug Status gain certain financial incentives such as a longer period of exclusivity, enhanced patent protection,…
Updated: Near-Term Catalysts And High Insider Ownership Make GTx An Attractive Buy
Today, we are going to take a comprehensive look at a small-cap biotech company with several near-term catalysts, a strong cash position, and high insider ownership. I feel with all factors considered, this company can see very good price appreciation…
Approaching Biopharma Catalyst Events
Today, I list 4 biopharmas I feel offer strong upside potential in the short and midterm. With these catalysts quickly approaching, we can expect some nice shorter term appreciation under normal market conditions. I feel the 4 stocks I list…
